Endo reviewing Anesiva notice on pain drug

<p>The notice referred to the patents that cover the method of use and formulation of Endo&#0039;s lidocaine-containing topical patch products, Lidoderm and Synera. <br /><br />If approved, Endo believes that Zingo will not be a generic to, nor will it compete with, Lidoderm because of Zingo&#0039;s indication and formulation. Anesiva&#0039;s notice stated that Zingo&#0039;s proposed indication is for preventing or reducing pain associated with blood draws and intravenous placements. <br /><br />Unlike Lidoderm, Zingo is not a topical patch. However, Endo believes that, although Zingo would not be a substitutable generic to Synera and uses a different delivery mechanism, Zingo may compete with Synera because their indications may be similar. Endo will continue to evaluate these notices.<br /><br />A new drug application for Zingo was filed in late 2006 and accepted for filing in January 2007.</p>